First-line fovinaciclib versus placebo combined with aromatase inhibitor for advanced breast cancer: A randomized, double-blind phase 3 study.

作者
Peng Yuan,Binghe Xu,Liu Y,Wei Li,Huiping Li,Zhongsheng Tong,Jing Cheng,Mingjuan Zhang,Jinlu Shan,Jincai Zhong,Tienan Yi,Jian Liu,Huihui Li,Zhen Huang,Jinsheng Wu,Sijuan Ding,Liang Li,Yuhui Peng,Xiaoran Yang,FCN-437c-III202 Investigators
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 1090-1090
标识
DOI:10.1200/jco.2026.44.16_suppl.1090
摘要

1090 Background: Endocrine therapy combined with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is the standard first-line therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Fovinaciclib is a novel CDK4/6 inhibitor that showed survival benefit when added to fulvestrant in the later-line setting. This randomized, double-blind, placebo-controlled phase 3 trial evaluated the efficacy and safety of fovinaciclib plus an aromatase inhibitor (AI) as initial therapy. Methods: Adult women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting were enrolled across 63 centers. Eligible patients were randomized in a 1:1 ratio to receive oral fovinaciclib (200 mg, once daily, days 1–21) or placebo plus an AI (letrozole 2.5 mg or anastrozole 1 mg, orally, once daily, days 1–28) in 28-day cycles. Pre- or perimenopausal patients also received goserelin (3.6 mg, subcutaneous, day 1). The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR). Secondary endpoints included other efficacy endpoints and safety. Results: A total of 417 patients were assigned to the fovinaciclib ( n = 208) or placebo arm ( n = 209) with balanced baseline characteristics. At the protocol-specified interim analysis (median follow-up 16.6 months, data cutoff date June 25, 2024), adding fovinaciclib significantly improved PFS (hazard ratio 0.55, 95% CI 0.38–0.77; p = 0.0003): median PFS was not reached in the fovinaciclib arm and 20.2 months (95% CI 16.4 months–not evaluable) in the placebo arm. The 2-year PFS rates were 65.5% (95% CI 55.3%–73.9%) and 38.9% (95% CI 27.5%–50.2%), respectively. Consistent PFS benefit was observed in investigator assessments (hazard ratio 0.49 [95% CI 0.36–0.68], p < 0.0001) and across most subgroups. Fovinaciclib also showed favorable results across secondary efficacy endpoints. OS data remain immature. Treatment-emergent adverse events (TEAEs) occurred in 207 (99.5%) and 199 (95.2%) patients in the fovinaciclib and placebo arms, respectively, with serious adverse events (SAEs) reported in 30 (14.4%) and 24 (11.5%). Discontinuation due to TEAEs was only 1.4% in both arms. The most common TEAEs were hematologic toxicities, which did not lead to SAEs or study drug discontinuation. Grade ≥3 gastrointestinal toxicities (2.4% versus 0) or renal toxicities (0 versus 0.5%) were rare. Conclusions: Adding fovinaciclib to first-line AI therapy provided a significant and clinically meaningful PFS benefit, along with consistent improvements in other survival outcomes and a manageable safety profile. These findings support fovinaciclib as a first-line treatment option for patients with HR-positive, HER2-negative advanced breast cancer. Clinical trial information: NCT05439499 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
BAEKHYUNLUCKY发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
尘_发布了新的文献求助10
2秒前
BernardGo发布了新的文献求助10
5秒前
荼蘼发布了新的文献求助10
5秒前
慈祥的丹寒完成签到 ,获得积分10
9秒前
9秒前
冯老三完成签到 ,获得积分10
10秒前
Maestro_S的应助被chuqing采纳,获得10
10秒前
howeVer完成签到 ,获得积分10
10秒前
槟洛完成签到,获得积分10
10秒前
月亮代表我的心完成签到,获得积分10
11秒前
黄大树完成签到,获得积分10
11秒前
高挑的伊完成签到,获得积分10
12秒前
正直的又柔完成签到,获得积分10
13秒前
丘比特的应助被老年学术废物采纳,获得10
13秒前
Long发布了新的文献求助10
13秒前
xixilulixiu完成签到 ,获得积分0
13秒前
渔舟完成签到 ,获得积分10
14秒前
马赛克完成签到,获得积分10
15秒前
荼蘼发布了新的文献求助10
15秒前
英俊的铭的应助被忧郁背包采纳,获得10
16秒前
海鲸完成签到,获得积分10
16秒前
bqys的应助被岳老师采纳,获得10
16秒前
17秒前
深情安青的应助被Eli采纳,获得10
17秒前
如约而至完成签到,获得积分10
18秒前
null的应助被墨北弋采纳,获得10
18秒前
所所的应助被wlei采纳,获得10
18秒前
18秒前
LL路完成签到 ,获得积分10
19秒前
19秒前
xlanister完成签到,获得积分20
19秒前
xzp发布了新的文献求助10
20秒前
moexce完成签到,获得积分10
20秒前
20秒前
21秒前
尘_完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566955
关于积分的说明 21789278
捐赠科研通 7769593
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241